TY  - JOUR
AU  - Cariou, B
AU  - Leiter, L A
AU  - Müller-Wieland, D
AU  - Bigot, G
AU  - Colhoun, H M
AU  - Del Prato, S
AU  - Henry, R R
AU  - Tinahones, F J
AU  - Letierce, A
AU  - Aurand, L
AU  - Maroni, J
AU  - Ray, K K
AU  - Bujas-Bobanovic, M
PY  - 2017
DO  - 10.1016/j.diabet.2017.01.004
UR  - http://hdl.handle.net/10668/11012
T2  - Diabetes & metabolism
AB  - The coadministration of alirocumab, a PCSK9 inhibitor for treatment of hypercholesterolaemia, and insulin in diabetes mellitus (DM) requires further study. Described here is the rationale behind a phase-IIIb study designed to characterize the efficacy...
LA  - en
KW  - Alirocumab
KW  - Diabetes
KW  - Insulin
KW  - LDL-C
KW  - ODYSSEY
KW  - PCSK9
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - Antibodies, Monoclonal, Humanized
KW  - Cardiovascular Diseases
KW  - Diabetes Mellitus, Type 1
KW  - Diabetes Mellitus, Type 2
KW  - Double-Blind Method
KW  - Drug Interactions
KW  - Female
KW  - Humans
KW  - Hypercholesterolemia
KW  - Insulin
KW  - Male
KW  - Middle Aged
KW  - Research Design
KW  - Risk Factors
KW  - Young Adult
TI  - Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial.
TY  - research article
VL  - 43
ER  -